急性成人歯性感染症患者を対象としたｃｅｆｃａｐｅｎｅ　ｐｉｖｏｘｉｌの臨床的検討

DOI 被引用文献1件 参考文献4件

書誌事項

タイトル別名
  • Clinical study on cefeapene pivoxil in adults with acute odontogenic infection

この論文をさがす

抄録

We studied the efficacy of cefcapene pivoxil (CFPN-PI, trade name: Flomox) against adult infection in dentistry and oral surgery for which oral antibiotics we are used.<BR>1) At 3 primary facilities and 9 secondary medical practice facilities nationwide, CFPN-PI was administered in 146 cases: 84 of periodontitis, 10 of pericoronitis, and 52 of jaw osteitis.The daily dose was 300mg in 139 and 450 mg in 7 cases.<BR>2) CFPN-PI was effective (judged by the primary physician) in 76 of 84 cases of periodontitis (90.5%), 8 of 10 of pericoronitis (80.0%), and 49 of 52 of jaw osteitis (94.2%), i.e., 133 overall (91.1%). Efficacy was higher at secondary than primary medical facilities at, 93.3% versus 87.7%.<BR>3) Efficacy, by age, was 84.8% in young adults (age: 17 to 45), 92.1% in middle-aged adults (age: 46 to 65), and 97.3% in older adults (age: 66 to 83). Eefficacy by daily dose was 91.4% in the 300 mg/day group and 85.7% in the 450 mg/day group.<BR>4) Efficacy judged on day 3 based on the Evaluation Standards of Antibiotic Efficacy in the Areas of Dentistry and Oral Surgery was 54 of 59 in periodontitis (91.5%), 5 of 7 in pericoronitis (85.7%), and 35 of 38 in jaw osteitis (92.1%), i.e., 95 of 104 overall (91.3%). It was higher at secondary than at primary medical facilities at, 92.9% versus 88.2%.<BR>5) When efficacy was compared to that at the new drug symposium, it was similar at 89.8% compared to 91.1% by the physician's judgment and 91.2% to 91.3% for day 3 judgment.<BR>6) Mild adverse reactions were observed in 2 of 153 cases (1.4%).<BR>Based on these results, we concluded that cefcapene pivoxil is a useful agent fortreating odontogenic infection in doses of 300mg/day.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ